Future Octopus arms

The world’s first adaptive clinical trial platform in progressive MS evaluating multiple treatments using a multi-arm, multi-stage (MAMS) design.

OCTOPUS are looking for new partnerships as OCTOPUS has the infrastructure and innovative design, to rapidly assess existing and new treatments that could slow down, or ultimately stop, the progression of disability in people with MS. Possible partnerships include collaboration with partners or industry looking int drug evaluation as well as other research studies.

Would your company be interested in working with OCTOPUS?

Adding treatments to an existing trial platform provides significant reduction in set up time as well as increased efficiency.

This is because OCTOPUS has:

• Established governance and management structures.
• A registration of interest portal with >2000 potential participants.
• 88% of participants screened proceeding to randomisation.
• UK sites open and recruiting with full MRI capacity.

If you may be interested in a partnership or would like more information on the trial, please feel free to contact us via the trial email mrcctu.octopus@ucl.ac.uk or any of the lead contacts below.

Best wishes

Professor Jeremy Chataway, OCTOPUS Chief Investigator (j.chataway@ucl.ac.uk)

Professor Max Parmar, Director of MRC CTU at UCL (m.parmar@ucl.ac.uk)

Professor Frederik Barkhof, UCL (f.barkhof@ucl.ac.uk)

Dr Emma Gray, Director of Research, MS Society (emma.gray@mssociety.org.uk)

On Behalf of the OCTOPUS Trial Management Team